Management includes maintaining adequate hydration (1.52 litres daily), rising slowly from sitting or lying positions, and taking small frequent meals
Warning: Significant Drug Interactions with Nirmatrelvir/Ritonavir Kit Nirmatrelvir/ritonavir kit includes ritonavir, a strong CYP3A inhibitor, which may lead to greater exposure of certain concomitant medications, resulting in potentially severe, life-threatening, or fatal events
Bone density screening (DEXA scan) should be discussed with your provider if you have lost more than 10 percent of body weight
Heres what the evidence currently suggests: Animal studies report mixed findings, some suggesting potential bone-protective effects, though human data is more limited
The systematic review of tirzepatide renal safety data found no increased risk of UTIs compared to placebo, insulin, or GLP-1 receptor agonists